Actualité
Physiogenex is sponsoring the PCSK9 conference on March 11th-13th in Nantes, FRANCE
Physiogenex is partnering the first international conference on PCSK9, a circulating protein that modulates LDL-cholesterol levels by degrading the LDL-receptor. Development of PCSK9 inhibitors represents a promising target, a proof of interest already validated in humans.
Read more
Physiogenex to present at the KinMet 2010 & ATVB 2010 annual conference in San Francisco, April 7th-10th, 2010
Physiogenex will present the effects of CETP inhibitor torcetrapib on macrophage-to-feces reverse cholesterol transport in the obese insulin resistant CETP-apoB100 transgenic mice.
Read more
Catalogue
Physiogenex to present at the American Heart Association (AHA) scientific sessions 2009, November 14th-18th; Orlando, FL, USA
Physiogenex is proud to present the effects of Liver-X -Receptor activation on macrophage-to-feces reverse cholesterol transport in dyslipidemic hamsters in vivo.
Physiogenex now provides the in vivo macrophage-to-feces reverse cholesterol transport experiment
Physiogenex offers the state-of-the-art technique to demonstrate that your compound promotes reverse cholesterol transport and has therefore the potential to prevent atherosclerosis and cardiovascular diseases.
Read more
Hypercholesterolemic hamster model
An original hamster nutritional model dedicated to mimic human hypercholesterolemia and specifically designed to cholesterol and lipoproteins studies.
Read more